Transcript Presentation 2-17-06

BME 273
Senior Design Project
Group 25
“MEMs in the Market”
Problem
Drug companies demand a MEMs device
that allows mobile, On-Chip drug testing,
but at this point, that demand has not been
met
Primary Objective
Our primary objective
is to create a MEMs
On-Chip dual cell
culture device at the
pico-liter volume
scale that allows for
automated cell
culturing and sensing
for the testing of
drugs and other
perfused substances.
Goals
Primary goal:


Create two cell cultures, each 720 pico-liter
volumes, on one chip according to previous
specifications
Show that these cell cultures allow for cells to
retain life during experiments
Secondary goals:

Create On-Chip sensors that allow us to
sense the metabolism/response of cells to
different stimuli (i.e., drugs)
Solution Original
Solution
Primary Design: (picture)
Solution Continued
Solution
Secondary Design:
Solution
Experimental Methods:
Load cells into device
Begin perfusion
Wait 24 hrs., 48 hrs., etc.
At different times periods test cell viability
via fluorescence
Test fluorescence via imaging
Materials
Polydimethlysiloxane (PDMS)
Negative Resist (SU-8)
Silicon Wafers
MEMS laboratory
8 mm masks
Platinum (working electrodes)
Silver (reference Ag/AgCl electrodes)
Fabrication Steps
Lay down SU-8 on silicon wafer, expose using
mask, and develop lower region for cell insertion
and perfusion.
Cast PDMS replica of master
Lay down SU-8 on silicon wafer, expose using
mask, and develop upper region for pneumatic
control of cell insertion channels.
Cast PDMS replica of master and then lay over
top of lower region
Business Strategy
Objective: Developing a strategy
to market this BioMEMS device to
major drug companies
Main Focus Points
Cost efficiency



Currently, $400-800 million and 10 years per drug
Lower cost due to decrease in reagent and labor
usage
<$1 per BioMEMS chip
Scale up the number of cell cultures per
experiment

Higher speed  faster experiments
Greater control and modularity

Portable experimentation
Market Barriers
Government regulation of medical devices
Reluctance of pharmaceutical industry to
universally invest lots of money
Lack of funding for BioMEMS start-up
companies
Scaling up production of prototypes
Market Potential
Worldwide MEMS market estimate
(in billions of $)
2003
2004
2005
2006
2007
3.85
4.5
5.4
6.2
7
Source: Yole Development
2005 forecast MEMS markets by sector
Automotive
Telecom
Bio-med
Military
Other
41%
29%
16%
3%
11%
Source: Peripheral Research Corp, Santa Barbara, Calif.
Industry Contacts
Pfizer
Johnson & Johnson
Novartis
MEMS Industry Group
Microchips, Inc.
ISSYS
Boehringer Ingelheim
Affymetrix, Inc.
Caliper Life Sciences
Cepheid
Orchid Cellmark
Roger H. Grace

Author “The New MEMS and
Their Killer Apps”
http://finance.yahoo.com
References
Fabrication of miniature Clark oxygen
sensor integrated with microstructure

Ching-Chou Wu, Tomoyuki Yasukawa, Hitoshi
Shiku, Tomokazu Matsue
A BioMEMS Review: MEMS Technology
for Physiologically Integrated Devices

AMY C. RICHARDS GRAYSON, REBECCA
S. SHAWGO, AUDREY M. JOHNSON,
NOLAN T. FLYNN, YAWEN LI, MICHAEL J.
CIMA, AND ROBERT LANGER